NPPB and cancer: In a subgroup of cancer patients with available biomarker data, NT-proBNP, but not hs-cTnT, was found to be useful for risk stratification (HR univariate: 1.28, HR multivariate considering risk factors and hs-cTnT: 1.26, p < 0.001 .